Compare Stocks: ENLV, FATE, IMRX, and IRD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.95 -13.3%	$8.39	$1.92 ▼ $31.50	$32.82M	1.52	71,363 shs	314,606 shs
FATE Fate Therapeutics	$2.51 +6.4%	$2.45	$0.91 ▼ $3.23	$292.56M	2.51	2.68 million shs	1.69 million shs
IMRX Immuneering	$4.23 +4.4%	$4.71	$2.90 ▼ $10.08	$273.68M	0.41	1.46 million shs	509,399 shs
IRD Opus Genetics	$3.84 +10.7%	$3.88	$1.04 ▼ $5.81	$317.05M	0.55	942,803 shs	1.04 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+0.18%	-51.11%	-74.21%	-81.75%	-89.46%
FATE Fate Therapeutics	+1.72%	-8.53%	-2.48%	+88.80%	+101.71%
IMRX Immuneering	-4.48%	-9.40%	-19.80%	-22.71%	+10.05%
IRD Opus Genetics	+1.76%	+13.77%	-14.53%	-32.09%	+204.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.95 -13.3%	$8.39	$1.92 ▼ $31.50	$32.82M	1.52	71,363 shs	314,606 shs
FATE Fate Therapeutics	$2.51 +6.4%	$2.45	$0.91 ▼ $3.23	$292.56M	2.51	2.68 million shs	1.69 million shs
IMRX Immuneering	$4.23 +4.4%	$4.71	$2.90 ▼ $10.08	$273.68M	0.41	1.46 million shs	509,399 shs
IRD Opus Genetics	$3.84 +10.7%	$3.88	$1.04 ▼ $5.81	$317.05M	0.55	942,803 shs	1.04 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+0.18%	-51.11%	-74.21%	-81.75%	-89.46%
FATE Fate Therapeutics	+1.72%	-8.53%	-2.48%	+88.80%	+101.71%
IMRX Immuneering	-4.48%	-9.40%	-19.80%	-22.71%	+10.05%
IRD Opus Genetics	+1.76%	+13.77%	-14.53%	-32.09%	+204.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	12,527.55% Upside
FATE Fate Therapeutics	2.29	Hold	$5.13	103.78% Upside
IMRX Immuneering	2.86	Moderate Buy	$17.57	315.30% Upside
IRD Opus Genetics	2.83	Moderate Buy	$10.77	180.01% Upside

Current Analyst Ratings Breakdown

Latest ENLV, FATE, IMRX, and IRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	IRD Opus Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/20/2026	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $18.00
7/17/2026	IRD Opus Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	IMRX Immuneering	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
7/8/2026	IMRX Immuneering	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
7/8/2026	IMRX Immuneering	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
7/6/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
7/6/2026	IRD Opus Genetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
FATE Fate Therapeutics	$6.32M	46.41	N/A	N/A	$1.80 per share	1.40
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
IRD Opus Genetics	$11.98M	26.50	N/A	N/A	$0.22 per share	17.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	8/24/2026 (Estimated)
FATE Fate Therapeutics	-$136.32M	-$1.09	N/A	N/A	N/A	-2,056.79%	-58.89%	-39.39%	8/11/2026 (Estimated)
IMRX Immuneering	-$56.03M	-$1.17	N/A	N/A	N/A	N/A	-31.93%	-29.92%	8/12/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.33	N/A	N/A	N/A	-892.36%	-338.88%	-191.21%	8/12/2026 (Estimated)

Latest ENLV, FATE, IMRX, and IRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	IMRX Immuneering	-$0.26	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	IRD Opus Genetics	-$0.15	N/A	N/A	N/A	$2.63 million	N/A
8/11/2026	Q2 2026	FATE Fate Therapeutics	-$0.28	N/A	N/A	N/A	$1.37 million	N/A
5/15/2026	Q1 2026	IMRX Immuneering	-$0.30	-$0.21	+$0.09	-$0.21	N/A	N/A
5/13/2026	Q1 2026	FATE Fate Therapeutics	-$0.29	-$0.26	+$0.03	-$0.26	$1.49 million	$1.30 million
5/12/2026	Q1 2026	IRD Opus Genetics	-$0.16	-$0.75	-$0.59	-$0.75	$2.93 million	$2.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	193.24	193.24
FATE Fate Therapeutics	N/A	5.85	5.85
IMRX Immuneering	N/A	32.45	32.45
IRD Opus Genetics	N/A	7.13	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
FATE Fate Therapeutics	97.54%
IMRX Immuneering	67.65%
IRD Opus Genetics	14.97%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
FATE Fate Therapeutics	4.74%
IMRX Immuneering	22.90%
IRD Opus Genetics	11.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	16.83 million	14.77 million	Optionable
FATE Fate Therapeutics	550	116.56 million	111.03 million	Optionable
IMRX Immuneering	60	64.70 million	49.88 million	Not Optionable
IRD Opus Genetics	14	82.57 million	72.91 million	N/A

ENLV, FATE, IMRX, and IRD Headlines

Recent News About These Companies

Opus Genetics (NASDAQ:IRD) COO Sells $13,653.36 in Stock

July 29 at 5:51 AM | insidertrades.com

ADAR1 Capital Management LLC Buys 1,809,004 Shares of Opus Genetics, Inc. $IRD

July 29 at 3:12 AM | marketbeat.com

Insider Selling: Opus Genetics (NASDAQ:IRD) COO Sells $13,653.36 in Stock

July 28 at 12:52 PM | marketbeat.com

Benjamin Yerxa Sells 7,429 Shares of Opus Genetics (NASDAQ:IRD) Stock

July 28 at 12:51 PM | marketbeat.com

Opus Genetics (NASDAQ:IRD) CFO Robert Gagnon Sells 7,783 Shares of Stock

July 28 at 12:51 PM | marketbeat.com

Opus Genetics (NASDAQ:IRD) CEO Sells 9,475 Shares

July 28 at 12:22 PM | marketbeat.com

Opus Genetics, Inc. (NASDAQ:IRD) Receives $10.77 Average Target Price from Brokerages

July 23, 2026 | americanbankingnews.com

Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of "Moderate Buy" from Analysts

July 18, 2026 | marketbeat.com

Opus Genetics (NASDAQ:IRD) Downgraded to "Strong Sell" Rating by Zacks Research

July 15, 2026 | marketbeat.com

Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)

July 11, 2026 | theglobeandmail.com

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

July 9, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Opus Genetics (IRD) and Vertex Pharmaceuticals (VRTX)

July 8, 2026 | theglobeandmail.com

Opus Genetics (NASDAQ:IRD) Receives "Buy" Rating from BTIG Research

July 6, 2026 | marketbeat.com

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

July 6, 2026 | globenewswire.com

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup

July 5, 2026 | finance.yahoo.com

5 Overlooked Penny Stocks to Buy Right Now

July 4, 2026 | insidermonkey.com

Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness

July 2, 2026 | tipranks.com

JonesTrading Sticks to Their Buy Rating for Opus Genetics (IRD)

June 27, 2026 | theglobeandmail.com

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

June 26, 2026 | globenewswire.com

Oppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)

June 19, 2026 | theglobeandmail.com

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

June 17, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, FATE, IMRX, and IRD Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.95 -0.30 (-13.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 +0.03 (+1.28%)

As of 05:23 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Fate Therapeutics NASDAQ:FATE

$2.51 +0.15 (+6.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.52 +0.01 (+0.40%)

As of 05:57 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Immuneering NASDAQ:IMRX

$4.23 +0.18 (+4.44%)

Closing price 04:00 PM Eastern

Extended Trading

$4.26 +0.03 (+0.71%)

As of 05:38 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Opus Genetics NASDAQ:IRD

$3.84 +0.37 (+10.66%)

Closing price 04:00 PM Eastern

Extended Trading

$3.89 +0.05 (+1.41%)

As of 05:48 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, FATE, IMRX, and IRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, FATE, IMRX, and IRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, FATE, IMRX, and IRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, FATE, IMRX, and IRD Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Fate Therapeutics NASDAQ:FATE

Immuneering NASDAQ:IMRX

Opus Genetics NASDAQ:IRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, FATE, IMRX, and IRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, FATE, IMRX, and IRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, FATE, IMRX, and IRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, FATE, IMRX, and IRD Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Fate Therapeutics NASDAQ:FATE

Immuneering NASDAQ:IMRX

Opus Genetics NASDAQ:IRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools